US-based Colossal Biosciences said it has raised $200 million (over ₹1,732 crore) in a TWG Global-led Series C funding round. The latest round values Colossal at $10.2 billion. The company, which has raised $435 million so far, said it’ll use the funds to advance its genetic engineering technologies. Colossal works to bring extinct species back to life using gene editing.